This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Paulos, C. M. Articles by Restifo, N. P. Search for Related Content PubMed PubMed Citation Articles by Paulos, C. M. Articles by Restifo, N. P. Related Collections Cancer Immunology Cancer Immunology: Immunotherapy Clinical Research: Clinical Trials

Toll-like Receptors in Tumor Immunotherapy

Authors' Affiliation: National Cancer Institute, NIH, Bethesda, Maryland

Requests for reprints: Nicholas P. Restifo or Chrystal M. Paulos, National Cancer Institute, NIH, Mark O. Hatfield Clinical Research Center, Room 3-5762, 10 Center Drive, Bethesda, MD 20892-1502. Phone: 301-496-4904; Fax: 301-496-0011; E-mail: restifo{at}nih.gov or chrystalp@hotmail.com.

Abstract

Lymphodepletion with chemotherapeutic agents or total body irradiation (TBI) before adoptive transfer of tumor-specific T cells is a critical advancement in the treatment of patients with melanoma. More than 50% of patients that are refractory to other treatments experience an objective or curative response with this approach. Emerging data indicate that the key mechanisms underlying how TBI augments the functions of adoptively transferred T cells include (a) the depletion of regulatory T cells (T_reg) and myeloid-derived suppressor cells that limit the function and proliferation of adoptively transferred cells; (b) the removal of immune cells that act as "sinks" for homeostatic cytokines, whose levels increase after lymphodepletion; and (c) the activation of the innate immune system via Toll-like receptor 4 signaling, which is engaged by microbial lipopolysaccharide that translocated across the radiation-injured gut. Here, we review these mechanisms and focus on the effect of Toll-like receptor agonists in adoptive immunotherapy. We also discuss alternate regimens to chemotherapy or TBI, which might be used to safely treat patients with advanced disease and promote tumor regression.

This article has been cited by other articles:

				G. C. Prendergast Breaking Immune Suppression in Cancer: The Emerging Revolution in Immunotherapy Cancer Reviews Online Content, October 1, 2007; 2007(7): 13 - 14. [Full Text] [PDF]

				G. Lizee, M. A. Cantu, and P. Hwu Less Yin, More Yang: Confronting the Barriers to Cancer Immunotherapy Clin. Cancer Res., September 15, 2007; 13(18): 5250 - 5255. [Abstract] [Full Text] [PDF]

				T. F. Gajewski Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment Clin. Cancer Res., September 15, 2007; 13(18): 5256 - 5261. [Abstract] [Full Text] [PDF]

				S. H. Wrzesinski, Y. Y. Wan, and R. A. Flavell Transforming Growth Factor-{beta} and the Immune Response: Implications for Anticancer Therapy Clin. Cancer Res., September 15, 2007; 13(18): 5262 - 5270. [Abstract] [Full Text] [PDF]